Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ataluren PK/PD in young children (2-5 years) with nmDMD
NCT02819557Phase 2Completed
- Sponsor
- PTC Therapeutics, Inc.
- Start
- Jun 2016
- Primary completion
- Feb 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of ataluren in Duchenne muscular dystrophy (DMD), sponsored by PTC Therapeutics, Inc.. Started Jun 2016; status: completed.
02
Drugs
ataluren
03
Conditions
Duchenne muscular dystrophy (DMD)
Beyond the preview
Go deeper on NCT02819557.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02819557.